Where Sarepta Therapeutics Stands With Analysts
Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Sarepta rapeutics
Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.
Benzinga ·
Expert Ratings for Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
